Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2019-01
-
To test the compounds metabolic stability we measured the
2024-10-17

To test the compounds metabolic stability, we measured the half-life of compounds and in mouse hepatic microsomes (1mg/mL) and found them to have modest stability, with half-lives of 7.5 and 2.9min respectively, indicating these compounds may be unsuitable for studies. In order to gain structura
-
br Conclusions The present protocol for localizing or spotti
2024-10-17

Conclusions The present protocol for localizing or “spotting” the site of action of an antioxidant in a micro-heterogeneous medium is based on the differences in its reactivity vis-à-vis the series of amphiphobic TEMPO derivatives 1a–f. Plots of the relative antioxidant effectiveness of a given A
-
234 2 mg br Economics consequences of antibiotic resistance
2024-10-17

Economics consequences of antibiotic resistance in a SICU In the era of cost-containment, surgeons also need to consider the economic impact of antibiotic resistance in the surgical patient. Antibiotic-resistant infections are more difficult to treat, are more costly and more likely to be fatal t
-
br Valsartan It is another ARB with several
2024-10-17

Valsartan It is another ARB, with several reports for its beneficial effects on CV system both in preclinical and clinical studies. Valsartan treatment has reduced the levels of pentraxin 3, a marker for inflammation and is well tolerated in terms of side effects [17]. In BSCORE study, 90-day sec
-
In the late s Solvay Pharmaceuticals discontinued
2024-10-16

In the late ‘90s, Solvay Pharmaceuticals discontinued the Phase 2 development of a promising potent and highly selective A1AR antagonist based on the pyrrolopyrimidine scaffold, SLV320 [43] (2, Chart 1, also named derenofylline; Ki hA1AR = 1 nM), for the treatment of acute heart failure [24]. In the
-
An alternative approach to the administration
2024-10-16

An alternative approach to the administration of ADO agonists is to amplify the actions of endogenous ADO by inhibiting the ADO-metabolizing enzyme, ADO kinase (AK). Inhibition of AK has the net effect of potentiating the local concentration and the effects of ADO in the extracellular compartment.
-
Previous studies suggest that TGF contributes to the pathoge
2024-10-16

Previous studies suggest that TGF-β contributes to the pathogenesis of diabetic renal injury [47]. TGF-β stimulates matrix production and prevents matrix degradation, which leads to increase collagen deposition and glomerulosclerosis [48]. In the current study ABT702 significantly reduced renal coll
-
hydroxydopamine OHDA is a selective
2024-10-16

6-hydroxydopamine (6-OHDA) is a selective catecholaminergic neurotoxin mainly used to generate lesions in the nigrostriatal pathway in rats (Ungerstedt, 1968). The most common use of 6-OHDA is via unilateral injection into the rat medial forebrain bundle (MFB). DA depletion, nigral DA cell loss, and
-
The synthesis and secretion of adrenal
2024-10-16

The synthesis and secretion of adrenal androgens is apparently unique to humans and nonhuman primates, and requires the expression of key mediators such as CYP17 [26]. Endocrine control of CYP17 expression in rhesus monkeys is comparable to that in humans [27]. An analysis of baboon cDNA for CYP17 s
-
Deferiprone australia br Conclusion br List of abbreviations
2024-10-16

Conclusion List of abbreviations Acknowledgment The studies performed by our laboratory and presented in this review were supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan, (KAKENHI 17590618 [to H.I.] and KAKENHI 22249017 [to Y.Y.]), and the Japanese S
-
br Autophagy and antiviral innate
2024-10-16

Autophagy and antiviral innate immunity signaling Viral manipulation of autophagy interfering with IFN-I synthesis We have seen that autophagy factors can down-regulate the production of IFN-I induced by RLR engagement during viral infection. In fibroblasts and epithelial cells, there exists c
-
br Conclusion br Acknowledgement This study
2024-10-16

Conclusion Acknowledgement This study was supported by NIH/NINDSR01 NS036812-16. Introduction Stroke is the leading cause of disability and the fifth leading cause of death in the United States (Writing Group et al., 2016). On average, every 4 min a human dies of stroke (Lackland et al., 2
-
Dopaminergic neurons are vulnerable to oxidative products an
2024-10-16

Dopaminergic neurons are vulnerable to oxidative products and inflammatory responses; these processes may play important roles in the etiology of PD. Because glial sulconazole receptor are the main generators of inflammatory responses in the CNS, the possibility that PD results from glial cell dysf
-
In summary the CV and
2024-10-15

In summary, the CV and renal benefits of sacubitril/valsartan in HF patients are attributed to the increased levels of peptides that are degraded by neprilysin and the simultaneous inhibition of the effects of AT1 receptor by valsartan (Fig. 1). Physical and chemical properties Sacubitril/Valsar
-
Moxifloxacin br Natriuretic peptides and neprilysin Left ven
2024-10-15

Natriuretic peptides and neprilysin Left ventricular systolic function, most commonly due to myocardial damage as a consequence of coronary artery disease, hypertension or both, and leading to sustained, pathological activation of the renin angiotensin Moxifloxacin system (RAAS) and sympathetic
15235 records 68/1016 page Previous Next First page 上5页 6667686970 下5页 Last page